BGMS— Bio Green Med Solution, Inc.

Consumer DiscretionaryBiotechnology$5M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Revenues	$747K+1637.2%	$43K-89.8%	$420K	$0
Cost of sales	$609K	—	—	—
Research and development	$848K-87.3%	$6.7M-65.3%	$19.2M-5.5%	$20.3M
General and administrative	$7.7M+43.1%	$5.4M-19.7%	$6.7M-9.0%	$7.4M
Total operating expenses	$9.2M-23.8%	$12.0M-53.4%	$25.9M-6.4%	$27.7M
Operating loss	-$8.4M+29.8%	-$12.0M+52.8%	-$25.5M+8.0%	-$27.7M
Foreign exchange losses	$73K+235.2%	-$54K+87.0%	-$414K-277.7%	$233K
Interest income	$62K+416.7%	$12K-95.5%	$266K+26.7%	$210K
Gain on deconsolidation of former subsidiary	$4.9M	—	—	—
Other income, net	$354K+580.8%	$52K+4.0%	$50K-96.1%	$1.3M
Total other income, net	$5.4M+54260.0%	$10K+110.2%	-$98K-105.6%	$1.7M
Loss before taxes	-$3.0M+75.1%	-$12.0M+53.1%	-$25.6M+1.4%	-$25.9M
Income tax benefit / (provision)	-$7K-100.9%	$782K-73.9%	$3.0M-36.5%	$4.7M
Net loss	-$3.0M+73.3%	-$11.2M+50.3%	-$22.6M-6.4%	-$21.2M
Dividend on convertible exchangeable preferred shares	-$61K	—	-$201K+0.0%	-$201K
Deemed dividend on warrant exchange	-$11.0M	—	—	—
Net loss applicable to common shareholders	-$14.1M-25.7%	-$11.2M+50.7%	-$22.8M-6.3%	-$21.4M
Net loss per share - basic (common shareholders)	-$6450.00+98.7%	-$502460.00-1878255.1%	-$26.75+6.8%	-$28.70
Net loss per share - diluted (common shareholders)	-$6450.00+98.7%	-$502460.00-1878255.1%	-$26.75+6.8%	-$28.70
Weighted average common shares outstanding - basic	2.19B+9692.4%	22.3M	—	—
Weighted average common shares outstanding - diluted	2.19B+9692.4%	22.3M	—	—
Product Revenue Fire Safety [Member]
Clinical Trial Supply [Member]

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 13 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.